



[Science](#)[Education](#)[Patient Care](#)

[Our Society](#)[Our Mission, Vision & Values](#)[EBMT Membership 2025](#)[Organisational Structure 2025](#)[Financial Highlights 2025](#)[EBMT Partners](#)

Breadcrumb

1. [Home](#)

Entity Print



Krzysztof Kalwak
PDWP Chair
Germany

Major achievements

The third year of the current PDWP term under the chairmanship of Krzysztof Kalwak was marked by exceptional **scientific productivity**, strengthened **multicentre collaborations**, and a strong **commitment to education**.

Several large **retrospective and registry-based studies** were advanced or initiated, leading to high-quality publications in leading international journals. These included analyses comparing $\alpha\beta$ T-cell-depleted versus post-transplant cyclophosphamide-based haploidentical HSCT in acute leukaemia, accepted as an oral presentation at ASH. Overall scientific output in 2025 reached a cumulative impact factor of 71, the second highest in the Working Party's history, highlighting the PDWP's ability to address clinically urgent questions and generate robust long-term outcome data through international collaboration.

New projects addressed emerging topics such as MSD cord blood transplantation in malignant and non-malignant disorders, allogeneic SCT for paediatric relapsed/refractory KMT2A-rearranged AML in complete remission, and outcomes in children with early post-transplant relapse in AML. Numerous abstracts were submitted to the Annual Meeting of EBMT and to ASH, many as joint initiatives with other EBMT Working Parties, underscoring the PDWP's collaborative spirit. Close collaboration within the Westhafen International Group, including colleagues from the US and Canada, resulted in the publication of two important white papers in top-ranked scientific journals.

Education remained a central pillar of PDWP activities. The **PDWP Educational Meeting** held in June 2025 in Wrocław brought together international faculty and highly engaged young investigators in a strong atmosphere of mentorship and scientific exchange. The **paediatric track at the 10th International Transplant and Cellular Therapy Course** further strengthened structured paediatric education within EBMT.

At the **Annual Meeting of EBMT** in March 2025 in Florence, the **Dietrich-Niethammer Award was presented to Professor Peter Bader** (Frankfurt), honouring his outstanding lifetime contributions to paediatric stem cell transplantation and his role as a leading figure within the PDWP community.



Dietrich-Niethammer Award to Peter Bader (Germany)

Throughout 2025, the PDWP continued to support **young investigators**, promote **harmonisation initiatives**, and foster inclusive, high-quality **scientific collaboration** across Europe and beyond.

Principal research studies

[Outcomes of pediatric patients with acute leukemias who received either post-transplant cyclophosphamide or a haploidentical transplant with TCR \$\alpha\beta\$ /CD19+ lymphocyte depletion](#)

[Study type](#)

[Retrospective Studies](#)

[Diseases](#)

[Acute Lymphatic Leukaemia \(ALL\)](#)

[Acute Myeloid Leukaemia \(AML\)](#)

[Group](#)

[Paediatric Diseases Working Party \(PDWP\)](#)

[Type of treatment](#)

[Allogeneic - Haploidentical](#)

[Principal investigator](#)

Franco Locatelli

Allogeneic vs autologous HSCT in B-cell NHL (D. Przystupski)

Study type

Retrospective Studies

Diseases

Non-Hodgkin's Lymphoma (NHL)

Group

Paediatric Diseases Working Party (PDWP)

Type of treatment

Allogeneic

Principal investigator

D. Przystupski

Outcomes of children with AML relapse within 6 months post HSCT (C. Horgan/R.

Wynn)

Study type

Retrospective Studies

Diseases

Acute Myeloid Leukaemia (AML)

Group

Paediatric Diseases Working Party (PDWP)

Type of treatment

Allogeneic

Principal investigator

Claire Horgan / Rob Wynn

Second allogeneic HSCT for relapsed pediatric ALL: a collaborative study on behalf of the Brazilian PDWP (SBTMO) and the European EBMT PDWP (J. Silva, C. Bonfim)

Study type

Retrospective Studies

Diseases

Acute Lymphatic Leukaemia (ALL)

Group

Paediatric Diseases Working Party (PDWP)

Type of treatment

Allogeneic

Principal investigator

Julia Silva, Carmen Bonfim

HSCT in patients with GLIS2+ AML study

Study type

[Retrospective Studies](#)

[Diseases](#)

[Acute Myeloid Leukaemia \(AML\)](#)

[Group](#)

[Paediatric Diseases Working Party \(PDWP\)](#)

[Type of treatment](#)

[Allogeneic](#)

[Principal investigator](#)

[Kanchan Rao](#)

Key publications

[2025](#)

[International expert consensus statement on PICU admission and early critical care management for paediatric patients following haematopoietic cell transplant and immune effector cell therapy](#)

[Group](#)

[Paediatric Diseases Working Party \(PDWP\)](#)

[WP/Committee not specified](#)

[1st listed author](#)

[Matteo Di Nardo](#)

[Journal](#)

[Lancet Child Adolesc Health.](#)

[2025](#)

[The hallmarks of hematopoietic stem cell transplantation for pediatric acute myeloid leukemia](#)

[Group](#)

[Paediatric Diseases Working Party \(PDWP\)](#)

[1st listed author](#)

[Eva Rettinger](#)

[Journal](#)

[Leukemia.](#)

[2025](#)

[Late effects after hematopoietic stem cell transplantation in patients with HLH: A Histiocyte Society, PDWP, IEWP, and TCWP EBMT Study](#)

[Group](#)

[Inborn Errors Working Party \(IEWP\)](#)

[Transplant Complications Working Party \(TCWP\)](#)

[Paediatric Diseases Working Party \(PDWP\)](#)

[1st listed author](#)

[Kim Ramme](#)

[Journal](#)

[J Allergy Clin Immunol.](#)

[2025](#)

[Single unrelated umbilical cord blood versus unmanipulated haploidentical HCT using PTCy in pediatric AML: a retrospective study on behalf of the EBMT PDWP and CTIWP](#)

[Group](#)

[Cellular Therapy & Immunobiology Working Party \(CTIWP\)](#)

[Paediatric Diseases Working Party \(PDWP\)](#)

[1st listed author](#)

[Benedetta Elena Di Majo](#)

[Journal](#)

[Bone Marrow Transplant.](#)

[2025](#)

[Harmonized immune recovery monitoring after HCT: evidence and practical guidance from the Westhafen Intercontinental Group](#)

[Group](#)

[Paediatric Diseases Working Party \(PDWP\)](#)

[1st listed author](#)

[Taymour Hammoudi](#)

[Journal](#)

[Blood Adv.](#)

[See the full list of the PDWP 2025 publications](#)



Indicators

	2023	2024	2025
Impact factor	26.20	65.50	71.10
Oral presentations	4	6	6
Poster presentations	2	4	5
Educational events	1	1	2

Major educational events




[Event](#)

51st Annual Meeting of the FBM



[Event](#)

10th International Transplant and Cellular Therapy Course



Event

Paediatric Diseases Working Party Educational Course

Jun 20, 2025 - Jun 22, 2025 / Wroclaw, Poland

Discover more

VISIT THE PDWP WEBPAGE